04322nam 2200961z- 450 991057687970332120231214133138.0(CKB)5720000000008378(oapen)https://directory.doabooks.org/handle/20.500.12854/84513(EXLCZ)99572000000000837820202206d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierPresent and Future of Personalised Medicine for Endocrine CancersBaselMDPI - Multidisciplinary Digital Publishing Institute20221 electronic resource (140 p.)3-0365-4330-9 3-0365-4329-5 Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients with endocrine cancers (e.g., thyroid and adrenocortical carcinoma). In particular, each patient can be considered as a unique, individual one, with unique genetic information. The aim of this Special Issue is to offer an overview of exciting new research in the area of endocrine tumours may set the stage for an innovative personalised management and precision medicine modalities for individualised care.New affordable individual genomic analyses, as well as the opportunity to test new compounds in primary cells may allow a personalised management of patients with endocrine malignancies. This approach may improve the prediction of clinical outcome and therapeutic effectiveness, as well as help to avoid the use of ineffective drugs. However, further efforts are needed to obtain an adjustment of clinical management in patients with endocrine cancers that would rely solely or in great part on genetic information. This Special Issue includes basic, translational, and clinical papers on personalised medicine in endocrine malignancies (i.e., thyroid and adrenal), especially focusing on diagnostic and prognostic biomarkers, as well as novel drug targets or targeted treatments, including eventual clinical trials.Medicinebicsscpapillary thyroid cancerSUV PET/CTBRAF V600Eimmune checkpoint inhibitors (ICIs)ipilimumabnivolumabprolactinomaCushing's diseaseaggressive pituitary tumoraggressive PitNETaggressive pituitary adenomapituitary carcinomaadrenocortical canceradrenal adenomasadrenal tumorsp53p27ki-67reticulinmitotaneadjuvant treatmentrecurrencerecurrence free survivaltimingintratumoral heterogeneitythyroid tumorBRAFRET/PTC rearrangementsRAS mutationadrenal cortexcarcinomaangiogenesisgene expressionosteopontinhyaluronan synthase 1multikinase inhibitorssorafeniblenvatinibdifferentiated thyroid cancerradioiodine resistancepredictive markerpredictorsresponse to treatmentsurvivalinformation needs and preferencesfocus group interviewpersonalized medicineneuroendocrine tumoursphaeochromocytomaparagangliomamolecular clustersMedicineRonchi Cristina Ledt1326491Altieri BarbaraedtRonchi Cristina LothAltieri BarbaraothBOOK9910576879703321Present and Future of Personalised Medicine for Endocrine Cancers3037560UNINA